Clinical TrialMay 26, 2026, 07:02 PM
MediciNova Completes Phase 2 Clinical Trial for MN-001
AI Summary
MediciNova, Inc. announced the completion of the last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202. This trial is evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The randomized, double-blind, placebo-controlled study involved patients receiving either 500 mg/day of MN-001 or placebo for 24 weeks. Top-line data from the trial are anticipated in the third quarter of 2026.
Key Highlights
- Completed Last Patient Last Visit (LPLV) for Phase 2 trial MN-001-NATG-202.
- Trial evaluates MN-001 (tipelukast) for hypertriglyceridemia and NAFLD associated with T2DM.
- Patients were randomized 1:1 to receive 500 mg/day of MN-001 or placebo for 24 weeks.
- Co-primary endpoints include change in liver fat content (CAP score) and fasting serum triglycerides.
- Top-line data from the study are expected in the third quarter of 2026.
Price Impact
More from MNOV